Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies

NCT03474640 is registered in ClinicalTrials.gov with TopAlliance Biosciences as lead sponsor.

NCT NCT03474640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03474640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
Lead sponsor
TopAlliance Biosciences
Phase
Phase 1
Overall status
Completed
Start date
February 21, 2018
Completion date
July 7, 2022
Enrollment
184 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies